However, the gene and protein expression of SEC13 is dramatically increased in colon cancer (CC) patients, which may be related to its glycolytic function, suggesting that SEC13 has opposite effects in different cancer backgrounds (Liu et al. 2022). This evidence concerns the gene SEC13 and colonic neoplasm.